Novo Nordisk A/s

Helle Birk Olsen

Peter Madsen

Frantisek Hubalek

Niels Christian Kaarsholm

Jeppe Sturis

Svend Havelund

Thomas Boerglum Kjeldsen

Mathias Norrman

Per Balschmidt

Kjeld Madsen

Svend Ludvigsen

Liselotte Bjerre Knudsen

Per Olaf Huusfeldt

Ulla Ribel-Madsen

Per Franklin Nielsen

Freddy Zimmerdahl Pedersen

Palle Jakobsen

Thomas Hoeg-Jensen

Ib Jonassen

Anders Klarskov Petersen

Thomas Børglum Kjeldsen

Morten Schlein

Dorte Bjerre Steensgaard

Tine Glendorf

Soren Ostergaard

Helle Naver

Soren Erik Bjorn

Anne Plum

S&oslash;ren Erik Bj&oslash;rn

Ulla Ribel

The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.

Insulin analogues and uses thereof

The invention is related to insulin compositions with a high content of zinc atoms per six molecules of acylated insulin. The insulin is an acylated insulin and may be mixed with a further insulin analogue such as the rapid acting insulin Asp B28 human insulin.

Insulin compositions and method of making a composition

The invention is related to fast acting insulin analogues which can form soluble mix-tures (pre-mixed or self-mixed) with long acting insulin analogues. The fast action is achieved through monomerizing substitutions/deletions in the C-terminus of the B-chain of human insulin and the mixability with long acting insulin analogues is achieved through a substitution of the Zn-binding His in position B10 of human insulin with a Gln amino acid residue. In one embodiment the invention is related to fast acting insulin analogues in which at least one of the natural amino acid residues in position B22-B30 in the human B-chain has been substituted with another amino acid residue having the effect of promoting formation of the monomeric form of insulin, the His amino acid residue in position 10 in the B-chain is substituted with a Gln and wherein further one or more of the amino acid residues in position B22-B30 optionally have been deleted.

Rapid acting insulin analogues

Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.

Preparation comprising insulin, nicotinamide and an amino acid

The present invention relates to pharmaceutical formulations comprising insulin, an insulin analog, an insulin derivative, or a combination of any of the foregoing, and a salt of protamine, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the insulin peptide(s) contained in such formulations is indicated. The present invention further relates to methods for increasing the stability and/or solubility of insulin in insulin-containing formulations at a pH less than 7.0 by adding a salt of protamine to the insulin-containing formulations.

Soluble, stable insulin-containing formulations with a protamine salt

The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

Derivatives of GLP-1 analogs

The present invention relates to novel ligands for the HisZnsites of the R-state insulin hexamer having the formula A-B-C-D-X (III), wherein: A is a chemical group which reversibly binds to a HisZnsites of an insulin hexamer; B is a linker; C is a fragment consisting of 0 to 5 neutral amino acids; D is a fragment comprising 1 to 20 positively charged groups independently selected from amino or guanidino groups; and X is &#x2014;OH, &#x2014;NHor a diamino group. The present invention also relates to R-state insulin hexamers comprising such ligands, and aqueous insulin preparations comprising such R-state insulin hexamers.

[object Object]

The present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action.

Growing community of inventors

Allerod, Denmark

Helle Birk Olsen